Aptimmune
Aptimmune Biologics develops and sells autogenous intranasal mucosal swine vaccines (PRRSV, IAV-S) using its patented Barricade platform and ZMAC cell line, selling direct to U.S. producers and veterinarians while licensing international rights to Kemin Biologics.
- Company typePrivate
- Founded2010
- HeadquartersSt Louis, United States
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What Aptimmune does
Aptimmune Biologics, Inc. is a St. Louis-based, venture-backed animal health biotechnology company founded in 2010 by Dr. Federico Zuckermann to commercialize mucosal vaccine technologies developed at the University of Illinois Urbana-Champaign. The company sells autogenous Barricade mucosal vaccines, administered intranasally, targeting Porcine Reproductive and Respiratory Syndrome virus (PRRSV) and Swine Influenza A virus (IAV-S), and is developing a vaccine for African Swine Fever virus (ASFV). Its core technology rests on the patented ZMAC porcine macrophage cell line and a naturally non-virulent PRRSV strain, which together enable intranasal delivery that elicits both innate and adaptive immunity and is not inhibited by maternally-derived antibodies, allowing earlier-age vaccination than conventional injectables.
The commercial portfolio consists of the Barricade Mucosal Vaccines line for PRRSV and IAV-S, the Barricade Technology Platform that underpins them, the ZMAC cell line sub-product used for diagnostic virus isolation and vaccine production, and an ASFV vaccine in development. Aptimmune generates revenue through direct, quote-based B2B sales of autogenous vaccines to U.S. swine producers and veterinarians on multi-year contracts, supplemented by an exclusive licensing/royalty arrangement with Kemin Biologics (formed 2018) that manufactures and markets the Barricade platform outside the U.S. Distribution in the U.S. is direct; distribution outside the U.S. runs through Kemin.
The company operates with 1-10 employees and has raised approximately $9 million across a Series A led by Arsenal Capital Management, a Series B led by Cultivation Capital, and a Yield Lab grant, with additional partnership equity from Kemin Industries. Aptimmune partners with Iowa State University's Veterinary Diagnostic Laboratory to use the ZMAC cell line for diagnostic PRRSV isolation, and engages Edge Veterinary Vaccine Consulting Group for USDA-CVB regulatory support. Leadership combines deep veterinary immunology research (Zuckermann, Senior Scientist Balaji Shanmugam) with senior animal-health commercial experience (CEO Vaibhav Nagpal, ex-Novus/Intervet/Kemin; Chairman Robert Nordgren).
Aptimmune firmographics
Firmographics- Name
- Aptimmune
- Legal name
- Aptimmune Biologics, Inc.
- Website
- https://aptimmune.com
- Company type
- Private
- Founded year
- 2010
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Aptimmune Biologics develops and sells autogenous intranasal mucosal swine vaccines (PRRSV, IAV-S) using its patented Barricade platform and ZMAC cell line, selling direct to U.S. producers and veterinarians while licensing international rights to Kemin Biologics.
- Ownership category
- akta.pro rank
Aptimmune industry classification
Industry- Product category
- Veterinary Biologics / Animal Vaccines
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Vaccine Technology Platforms (Live, Inactivated, Subunit, Vector, mRNA/DNA) (HLAMAKAH)
- akta.pro secondary industries
- Autogenous (Herd-Specific) Vaccines (HLAMAKAF), Vaccine Delivery & Administration Systems (needle-free, microneedle patches, intranasal/oral) (HLAAAEAF)
Keywords
Where Aptimmune is headquartered
LocationHeadquarters
- HQ city
- St Louis
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
Aptimmune business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Revenue model
- Swine Vaccine Sales: Revenue generated from selling autogenous mucosal vaccines (Barricade formulations) to swine producers and veterinarians for PRRSV, IAV-S, and ASF prevention
- Technology Licensing: Licensing of Barricade technology to Kemin Biologics for markets outside the US
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | Autogenous vaccine products for swine producers |
Go-to-market motion2 records
Distribution channels2 records
Marketing channels5 records
Aptimmune product offering
Product offeringCore offering
Aptimmune Biologics develops and commercializes inactivated autogenous mucosal (intranasal) vaccines for swine, built on its patented Barricade platform and ZMAC porcine macrophage cell line. The company's commercial products target PRRSV and Influenza A virus in swine (IAV-S), with additional R&D focused on an African Swine Fever virus (ASFV) vaccine.
Product overview
Aptimmune Biologics is a swine biologics company offering a portfolio of mucosal vaccines built on the Barricade Technology Platform. The platform is anchored by the patented ZMAC porcine macrophage cell line and mucosal (intranasal) delivery formulation. The commercial product line centers on Barricade Mucosal Vaccines targeting two major viral respiratory pathogens — PRRSV (Porcine Reproductive and Respiratory Syndrome Virus) and IAV-S (Influenza A virus in swine) — with additional R&D focused on an African Swine Fever Virus (ASFV) vaccine. All vaccines are inactivated, mucosal formulations administered intranasally, providing advantages over conventional injectable vaccines.
Differentiator
Problem solved
Functional benefit
Brands
- Barricade: Aptimmune's proprietary mucosal vaccine technology platform for swine diseases including PRRSV and IAV-S vaccines.
Products and services
- Barricade Mucosal Vaccines (PRRSV and IAV-S) Autogenous inactivated mucosal (intranasal) swine vaccines that elicit both innate and adaptive immunity, providing a fast immune response not inhibited by maternally-derived antibodies. The line addresses Porcine Reproductive and Respiratory Syndrome virus (PRRSV) and Influenza A virus in swine (IAV-S) and is sold to U.S. swine producers and veterinarians for early-age vaccination programs.
- Barricade Technology Platform Enabling vaccine technology platform that combines Aptimmune's patented ZMAC porcine macrophage cell line with intranasal mucosal delivery formulation. The platform underpins Aptimmune's PRRSV and IAV-S vaccines and is licensed exclusively to Kemin Biologics for manufacturing and sale outside the United States.
- ZMAC Porcine Macrophage Cell Line Patented scalable porcine macrophage cell line derived from porcine alveolar macrophages, specialized for PRRSV isolation and efficient growth of economically important swine viruses including PRRSV and IAV-S. Licensed for use by diagnostic and research partners (e.g., Iowa State University) and used in Aptimmune's vaccine production.
Quantifiable outcome
- Over $1 billion annual economic impact addressed through PRRSV vaccination
- +1 more outcomes
Companies that use Aptimmune
Customer profileSegments3 records
Ideal customer profiles2 records
Aptimmune technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Aptimmune partnerships and signals
Strategic signalPartnerships
Three partnerships are on record, tiered core and minor.
- Kemin Industries / Kemin BiologicscoreKemin Industries acquired equity position in Aptimmune and formed Kemin Biologics to manufacture and market Aptimmune's Barricade swine vaccine technology outside the US. Kemin has exclusive rights to vaccines and technologies in international markets while Aptimmune retains US market responsibilities.
- Iowa State University Veterinary Diagnostic LaboratorycorePartnership enabling Iowa State to use Aptimmune's patented ZMAC cell line to isolate PRRSV from diagnostic samples, improving success rates of PRRSV isolation for autogenous vaccine production.
- Edge Veterinary Vaccine Consulting GroupminorPartnership with consulting group comprised of former CVB and industry regulatory professionals to advise on USDA-CVB regulatory matters and assist with lead generation, screening and manufacturing guidance.
Scale indicators6 records
Recent moves7 records
Expansion highlights5 records
Aptimmune competitors and assessment
Company assessmentBroad incumbents
- Boehringer Ingelheim Animal Health: Largest animal health player globally and the dominant incumbent in PRRSV vaccines (Ingelvac PRRS). Directly competes with Aptimmune's Barricade PRRSV product in the same US swine customer base, but operates as a broad-line animal health company across many species.
- Zoetis: Largest pure-play animal health company, with a swine respiratory vaccine portfolio including FluSure/IAV-S and Fostera PRRSV. Competes with Aptimmune for US swine producer vaccine budgets, though as part of a much broader portfolio spanning companion animals, livestock and diagnostics.
- Merck Animal Health (MSD Animal Health): Major animal health incumbent with established PRRSV vaccines (e.g., PRIME PAC) and a global swine portfolio. Targets the same swine veterinarians and producers as Aptimmune, with much larger commercial and R&D resources.
- Elanco Animal Health: Broad-line animal health company offering swine respiratory solutions including IAV-S and PRRSV products. Competes with Aptimmune's Barricade line in US swine accounts as part of a diversified livestock and companion animal portfolio.
Direct peers
- Phibro Animal Health: Animal health company with a meaningful swine vaccine portfolio targeting respiratory and reproductive pathogens in pigs. Closely comparable to Aptimmune in its swine-focused commercial model and vaccine-led approach.
- Ceva Santé Animale: Global animal health vaccine specialist with a significant swine business (including Cevac and Hu/Lin vaccines). A direct peer in swine vaccine technology and in marketing mucosal/intranasal-style products to global pork producers.
- HIPRA: Spain-based animal health vaccine company with a focused swine portfolio, including autogenous and conventional vaccines for PRRSV and IAV-S. Closely comparable to Aptimmune in its vaccine-specialist positioning and swine emphasis.
- IDT Biologika: Veterinary vaccines and biopharmaceutical CDMO with a swine vaccine portfolio, including autogenous options. Comparable to Aptimmune in swine vaccine development, autogenous capabilities and mucosal/intranasal research.
- Vaxxinova: Animal health company focused on autogenous and customized vaccines for livestock, including swine. Most directly comparable peer to Aptimmune on the autogenous-vaccine business model and herd-specific PRRSV/IAV-S offerings.
- Newport Laboratories (a Boehringer Ingelheim company): Autogenous vaccine manufacturer for swine and other livestock, now part of Boehringer Ingelheim. Direct competitor to Aptimmune's autogenous Barricade business in the US swine market and on autogenous PRRSV/IAV-S products.
Market position
Strengths4 records
Weaknesses5 records
Competitive moat4 records
Key risks7 records
Key highlights6 records
Customer concentration
Aptimmune social profiles
Digital presenceAptimmune financial estimates
Financial estimateRevenue estimate
Valuation estimate
Aptimmune leadership team
Management profileNumber of profiles
Profiles8 records
Aptimmune funding detail
Funding detailFunding overview
Funding rounds5 records
Investors10 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Aptimmune M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Aptimmune
What does Aptimmune do?
Aptimmune Biologics develops and commercializes inactivated autogenous mucosal (intranasal) vaccines for swine, built on its patented Barricade platform and ZMAC porcine macrophage cell line. The company's commercial products target PRRSV and Influenza A virus in swine (IAV-S), with additional R&D focused on an African Swine Fever virus (ASFV) vaccine.
Is Aptimmune a public or private company?
Aptimmune is a private company. It is classified as venture growth investor backed and is currently operating.
When was Aptimmune founded?
Aptimmune was founded in 2010. It employs 1 to 10 people.
Where is Aptimmune based?
Aptimmune is headquartered in St Louis, United States, in the North America region.
How does Aptimmune make money?
Two revenue lines are on record. Swine Vaccine Sales are the primary driver. The others are technology Licensing.
Who are Aptimmune's main competitors?
Broad incumbents on record are Boehringer Ingelheim Animal Health, Zoetis, Merck Animal Health (MSD Animal Health) and Elanco Animal Health. Direct peers are Phibro Animal Health, Ceva Santé Animale, HIPRA, IDT Biologika, Vaxxinova and Newport Laboratories (a Boehringer Ingelheim company).
Does Aptimmune have an API?
No public API is recorded for Aptimmune.
What industry is Aptimmune in?
Aptimmune's product category is Veterinary Biologics / Animal Vaccines. Its primary akta.pro industry code is HLAMAKAH, Vaccine Technology Platforms (Live, Inactivated, Subunit, Vector, mRNA/DNA), with a secondary code of HLAMAKAF, Autogenous (Herd-Specific) Vaccines. Its NAICS code is 325414 and its SIC code is 2836.